Cocrystal Pharma, Inc. (NASDAQ:COCP) has a beta value of 0.74 and has seen 353,000,000 shares traded in the recent trading session. The company, currently valued at $220.48 Million, closed the recent trade at $2.78 per share which meant it gained $1.54 on the day or 124.38% during that session. The COCP stock price is -16.19% off its 52-week high price of $3.23 and 72.66% above the 52-week low of $0.76. If we look at the company’s 10-day average daily trading volume, we find that it stood at 590.72 Million shares traded. The 3-month trading volume is 1.45 Million shares.
The consensus among analysts is that Cocrystal Pharma, Inc. (COCP) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.04.
Cocrystal Pharma, Inc. (NASDAQ:COCP) trade information
Sporting 124.38% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, May 04 when the COCP stock price touched $2.9 or saw a rise of 12.59%. Year-to-date, Cocrystal Pharma, Inc. shares have moved 86.4%, while the 5-day performance has seen it change 104.44%. Over the past 30 days, the shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) have changed 77.27%. Short interest in the company has seen 2.12 Million shares shorted with days to cover at 1.46.
Wall Street analysts have a consensus price target for the stock at $4.25, which means that the shares’ value could jump 52.88% from the levels at last check today. The projected low price target is $4 while the price target rests at a high of $4.5. In that case, then, we find that the latest price level in today’s session is +61.87% off the targeted high while a plunge would see the stock lose 43.88% from the levels at last check today.
Cocrystal Pharma, Inc. (COCP) estimates and forecasts
Figures show that Cocrystal Pharma, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +48.49% over the past 6 months, with this year growth rate of 0%, compared to 8.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 20% and 42.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be +19.2%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +40.7% over the past 5 years. Earnings growth for 2021 is a modest +88.4%.
Cocrystal Pharma, Inc. (NASDAQ:COCP)’s Major holders
Insiders own 27.86% of the company shares, while shares held by institutions stand at 14.23% with a share float percentage of 19.73%. Investors are also buoyed by the number of investors in a company, with Cocrystal Pharma, Inc. having a total of 33 institutions that hold shares in the company. The top two institutional holders are Renaissance Technologies, LLC with over 3.95 Million shares worth more than $5.37 Million. As of December 30, 2020, Renaissance Technologies, LLC held 13.2% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 1.96 Million shares as of December 30, 2020. The firm’s total holdings are worth over $2.66 Million and represent 6.54% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 4.02% shares in the company for having 1201742 shares of worth $1.63 Million while later fund manager owns 663.62 Thousand shares of worth $902.53 Thousand as of December 30, 2020, which makes it owner of about 2.22% of company’s outstanding stock.